Drug Trial Radar · NCT01785472
Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension
Last checked: Nov 19, 2026Latest source record: Dec 29, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,438
Actual
Start
Apr 2013
Primary completion
Aug 2014
Study completion Aug 2014
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Feb 7, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the efficacy and safety of multiple doses of LCZ696 compared to olmesartan in Asian patients with essential hypertension
Conditions
- Essential Hypertension
Interventions
LCZ696Drug
LCZ696 200 mg tablet
OlmesartanDrug
Olmesartan 20 mg capsule
Placebo of LCZ696Drug
Placebo tablet of LCZ696 200 mg once daily
Placebo of OlmesartanDrug
Placebo capsule of olmesartan 20 mg once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Between LCZ696 200 mg Versus Olmesartan 20 mgTime frame: baseline, 8 weeks
Locations
50 sites in 7 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Fuzhou, China
Novartis Investigative Site
Shanghai, China
Novartis Investigative Site
Shanghai, China
Novartis Investigative Site
Shanghai, China
Novartis Investigative Site
Tianjin, China
Novartis Investigative Site
Beijing, Beijing Municipality, China
Novartis Investigative Site
Chongqing, Chongqing Municipality, China
Novartis Investigative Site
Chongqing, Chongqing Municipality, China
Novartis Investigative Site
Fuzhou, Fujian, China
Novartis Investigative Site
Guangzhou, Guangdong, China
Novartis Investigative Site
Nanning, Guangxi, China
Novartis Investigative Site
Shijiazhuang, Hebei, China
Novartis Investigative Site
Harbin, Heilongjiang, China
Novartis Investigative Site
Wuhan, Hubei, China
Novartis Investigative Site
Changsha, Hunan, China
Novartis Investigative Site
Nanjing, Jiangsu, China
Novartis Investigative Site
Suzhou, Jiangsu, China
Novartis Investigative Site
Nanchang, Jiangxi, China
Novartis Investigative Site
Shenyang, Liaoning, China
Novartis Investigative Site
Shanghai, Shanghai Municipality, China
Novartis Investigative Site
Shanghai, Shanghai Municipality, China
Novartis Investigative Site
Xi’an, Shanxi, China
Novartis Investigative Site
Xi’an, Shanxi, China
Novartis Investigative Site
Tianjin, Tianjin Municipality, China
Novartis Investigative Site
Hangzhou, Zhejiang, China
Novartis Investigative Site
Hong Kong, Hong Kong, Hong Kong
Novartis Investigative Site
Quezon City, Philippines
Novartis Investigative Site
Quezon City, Manila, Philippines
Novartis Investigative Site
Singapore, Singapore, Singapore
Novartis Investigative Site
Seoul, Korea, South Korea
Novartis Investigative Site
Seoul, Korea, South Korea
Novartis Investigative Site
Seoul, Korea, South Korea
Novartis Investigative Site
Seoul, Korea, South Korea
Novartis Investigative Site
Koyang, Kyunggi, South Korea
Novartis Investigative Site
Douliu, Taiwan
Novartis Investigative Site
Kaohsiung City, Taiwan
Novartis Investigative Site
Kaohsiung City, Taiwan
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.